Floatz logo

Alpha-Interferon

Kidney Cancer

Dartmouth-Hitchcock Medical CenterPhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
73/ 100

Competitive context

70 Active assets in the Kidney Cancer cohort.

Asset / SponsorPhaseRating
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
Girentuximab
Heidelberg Pharma AG
Phase 3BB
FILGRASTIM
National Institutes of Health Clinical Center (CC)
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB
Ifosfamide
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →